MX2016000464A - Incremento del potencial osteogenico de los injertos oseos. - Google Patents

Incremento del potencial osteogenico de los injertos oseos.

Info

Publication number
MX2016000464A
MX2016000464A MX2016000464A MX2016000464A MX2016000464A MX 2016000464 A MX2016000464 A MX 2016000464A MX 2016000464 A MX2016000464 A MX 2016000464A MX 2016000464 A MX2016000464 A MX 2016000464A MX 2016000464 A MX2016000464 A MX 2016000464A
Authority
MX
Mexico
Prior art keywords
enhancement
bone grafts
osteogenic potential
invention concerns
vivo treatment
Prior art date
Application number
MX2016000464A
Other languages
English (en)
Spanish (es)
Inventor
Jill Helms
Girija Dhamdhere
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2016000464A publication Critical patent/MX2016000464A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645—Connective tissue
    • A61L27/365—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
MX2016000464A 2013-07-16 2014-07-16 Incremento del potencial osteogenico de los injertos oseos. MX2016000464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361957946P 2013-07-16 2013-07-16
PCT/US2014/046852 WO2015009829A2 (en) 2013-07-16 2014-07-16 Enhancement of osteogenic potential of bone grafts

Publications (1)

Publication Number Publication Date
MX2016000464A true MX2016000464A (es) 2016-04-07

Family

ID=52346837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000464A MX2016000464A (es) 2013-07-16 2014-07-16 Incremento del potencial osteogenico de los injertos oseos.

Country Status (12)

Country Link
US (4) US9301980B2 (https=)
EP (1) EP3021943B1 (https=)
JP (2) JP6557659B2 (https=)
KR (1) KR102307174B1 (https=)
CN (2) CN105431202B (https=)
AU (2) AU2014290042B2 (https=)
CA (1) CA2916898A1 (https=)
GB (2) GB2530224B (https=)
IL (1) IL243288B (https=)
MX (1) MX2016000464A (https=)
WO (1) WO2015009829A2 (https=)
ZA (1) ZA201600095B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3328453B1 (en) 2015-07-31 2021-03-24 DePuy Synthes Products, Inc. Method of preparing an osteogenic bone graft
US11491262B2 (en) * 2018-04-19 2022-11-08 Paulo Jose PASQUALI Method of bone regeneration
US20210079079A1 (en) * 2018-05-02 2021-03-18 Ortheus, Inc. Systems and methods for local modulation of wnt signaling
CN111700881B (zh) * 2020-07-02 2021-05-18 四川大学 Wnt蛋白＼ZIF-8纳米复合体、其制备方法及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545412A (en) 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US5705655A (en) 1992-12-17 1998-01-06 Megabios Corporation Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
EP0730405A4 (en) 1993-11-24 1997-02-19 Megabios Corp AMPHIPHILE GUANIDINE DERIVATIVES
NZ277614A (en) 1993-11-24 1998-05-27 Megabios Corp Piperazine-containing amphiphiles and their use in liposomes for delivering genetic material intracellularly
AU696881B2 (en) 1994-06-22 1998-09-24 Megabios Corporation Cationic amphiphiles
DE19521412A1 (de) 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
AU2001295010A1 (en) * 2000-08-18 2002-03-04 Case Western Reserve University Regulator gene and system useful for the diagnosis and therapy of osteoporosis
US6723131B2 (en) * 2001-02-28 2004-04-20 The Cleveland Clinic Foundation Composite bone marrow graft material with method and kit
EP1660663A4 (en) * 2003-08-12 2007-07-11 Brigham & Womens Hospital METHOD AND COMPOSITIONS FOR TISSUE REPAIR
US8343922B2 (en) * 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
CN1846793B (zh) * 2005-04-14 2011-08-03 南方医院 一种组织工程骨及其构建与应用
WO2008109119A2 (en) * 2007-03-05 2008-09-12 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods of use thereof
WO2009073186A1 (en) 2007-12-03 2009-06-11 The Regents Of The University Of California Oxsterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
JP5458238B2 (ja) * 2007-11-30 2014-04-02 一郎 小野 臓器再生用デバイス
CA2734446C (en) * 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
WO2010111278A1 (en) * 2009-03-23 2010-09-30 The Texas A&M University System Compositions of mesenchymal stem cells to regenerate bone
WO2012034070A1 (en) * 2010-09-09 2012-03-15 The Board Of Trustees Of The Leland Stanford Junior University Use of liposomal wnt compositions to enhance osseointegration
WO2012135176A2 (en) * 2011-03-28 2012-10-04 The Board Of Trustees Of The Leland Stanford Junior University The use of wnt agents to prevent hypoxic injury

Also Published As

Publication number Publication date
KR102307174B1 (ko) 2021-10-01
JP6557659B2 (ja) 2019-08-07
AU2019222935A1 (en) 2019-09-19
JP6897996B2 (ja) 2021-07-07
IL243288A0 (en) 2016-02-29
AU2019222935B2 (en) 2021-09-09
AU2014290042B2 (en) 2019-06-20
KR20160032125A (ko) 2016-03-23
GB2578557A (en) 2020-05-13
WO2015009829A2 (en) 2015-01-22
WO2015009829A3 (en) 2015-11-12
CN111643733A (zh) 2020-09-11
US9301980B2 (en) 2016-04-05
EP3021943B1 (en) 2023-09-13
EP3021943A2 (en) 2016-05-25
CN105431202A (zh) 2016-03-23
GB202001056D0 (en) 2020-03-11
GB201600149D0 (en) 2016-02-17
US20170056556A1 (en) 2017-03-02
GB2578557B (en) 2020-09-02
US20150050249A1 (en) 2015-02-19
US9925304B2 (en) 2018-03-27
US10568989B2 (en) 2020-02-25
CA2916898A1 (en) 2015-01-22
IL243288B (en) 2021-01-31
JP2019177224A (ja) 2019-10-17
US11771803B2 (en) 2023-10-03
JP2016524989A (ja) 2016-08-22
GB2530224B (en) 2020-08-05
US20200147267A1 (en) 2020-05-14
GB2530224A (en) 2016-03-16
CN105431202B (zh) 2020-03-24
US20180140743A1 (en) 2018-05-24
EP3021943A4 (en) 2017-02-15
ZA201600095B (en) 2021-09-29
CN111643733B (zh) 2023-07-28
AU2014290042A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
MX2016010293A (es) Micro-organoides, y metodos de fabricacion y usos los mismos.
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
SG10201810723VA (en) Improved t cell compositions
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
EP4640273A3 (en) Inducible caspases and methods for use
WO2016070166A3 (en) Messenger una molecules and uses thereof
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
PH12014501844B1 (en) Peptidomimetic macrocycles
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
EP3687546A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEART DISEASE WITH REDIRECTED T-LYMPHOCYTE IMMUNOTHERAPIES
MX359769B (es) Metodos para descelularizar huesos.
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
WO2017055613A3 (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
WO2014134084A3 (en) Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
MX2016016756A (es) Terapia con células madre en patologías endometriales.
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
PH12017501070A1 (en) Peptides and their use in the treatment of skin
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
GB2530224A (en) Enhancement of osteogenic potential of bone grafts
AU2018262805A1 (en) Peptides for treatment of diabetes
EP3152297A4 (en) Use of anti-aging glycopeptides to enhance pancreatic cell health, survival and improve transplant outcome